<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310034</url>
  </required_header>
  <id_info>
    <org_study_id>NL61204.068.17</org_study_id>
    <nct_id>NCT03310034</nct_id>
  </id_info>
  <brief_title>NAD Supplementation Study</brief_title>
  <acronym>NADS</acronym>
  <official_title>The Effects of NAD+-Precursor Supplementation on Energy Metabolism in Physically Compromised Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project aims to determine whether supplementing with a mixture of the
      NAD+-precursors NA, NAM, and tryptophan can stimulate skeletal muscle mitochondrial function
      in physically compromised, elderly humans. Outcomes are related to mitochondrial function,
      energy metabolism, and physical function will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, dubbel-blind, cross-over trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ex vivo mitochondrial respiration</measure>
    <time_frame>After 4 weeks of supplementation.</time_frame>
    <description>Ex vivo mitochondrial function in skeletal muscle measured by oxygen consumption in muscle fibres (muscle biopsy vastus lateralis) on lipid-derived and carbohydrate-derived substrates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basal metabolic rate</measure>
    <time_frame>After 4 weeks of supplementation.</time_frame>
    <description>Basal metabolic rate expressed as kcal/kg/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In vivo mitochondrial capacity</measure>
    <time_frame>After 4 weeks of supplementation.</time_frame>
    <description>In vivo mitochondrial capacity measured with 31P-MRS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Submaximal exercise energy expenditure</measure>
    <time_frame>After 4 weeks of supplementation.</time_frame>
    <description>Submaximal exercise energy expenditure expressed as kcal/kg/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>After 4 weeks of supplementation.</time_frame>
    <description>Glucose tolerance measured by oral glucose tolerance test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic lipid accumulation</measure>
    <time_frame>After 4 weeks of supplementation.</time_frame>
    <description>Liver and skeletal muscle lipid accumulation measured with H-MRS in vivo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetylcarnitine levels</measure>
    <time_frame>After 4 weeks of supplementation.</time_frame>
    <description>Skeletal muscle acetylcarnitine levels measured with H-MRS in vivo, before and after exercise stimulation (cycling).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>After 4 weeks of supplementation.</time_frame>
    <description>Measured by Short Physical Performance Battery and Frailty criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Aging</condition>
  <condition>Mitochondrial Function</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NAD-precursors</intervention_name>
    <description>Intervention product containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan (total of 204 NE per serving) in a whey protein source for 31 days.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control product containing amino-acid mixture resembling whey-protein not containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan. To be taken for 31 days.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  Age ≥ 65 ≤ 75 years;

          -  BMI ≥ 20 kg/m2 ≤ 30 kg/m2;

          -  Normal physical activity levels: maximum of 1 hour per week engagement in a structured
             exercise session;

          -  SPPB score 4-9 and (pre-)frail;

          -  Subject should be in sufficient health to participate in the experiments, to be judged
             by the responsible physician based on the subject's medical history.

        Exclusion Criteria:

          -  Not meeting all inclusion criteria;

          -  Smoking;

          -  Excessive alcohol use and/or drug abuse;

          -  Subjects with diabetes mellitus type 2;

          -  Significant food allergies or intolerances concerning the study products;

          -  Participation in another biomedical study within 1 month before the first study visit,
             possibly interfering with the study results;

          -  Medication use known to hamper subject's safety during the study procedures;

          -  Subjects who use selective serotonin re-uptake inhibitors (SSRI), or selective
             norepinephrin re-uptake inhibitors (SNRI), or monoamino oxidase inhibitors
             (MAO-inhibitors), or clomipramine, or St. John's wort (Hypericum perforatum);

          -  Subjects with contra-indications for MRI;

          -  Subjects who do not want to be informed about unexpected medical findings;

          -  Subjects who do not want that their treating physician to be informed;

          -  Co-morbidities to which the intervention or program the may pose as a complicating
             factor;

          -  Inability to participate and/or complete the required measurements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Niels Connell, MSc</last_name>
    <phone>0031 43 3881587</phone>
    <email>n.connell@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Schrauwen, PhD</last_name>
    <phone>0031 43 3881502</phone>
    <email>p.schrauwen@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Connell, MSc</last_name>
      <phone>+31433881587</phone>
      <email>n.connell@maastrichtuniversity.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University</investigator_affiliation>
    <investigator_full_name>Patrick Schrauwen</investigator_full_name>
    <investigator_title>Prof. Dr. P. Schrauwen</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

